Clinical trials / NCT07833085
Recruiting

CAIX-targeted PET/CT in Solid Tumors

Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the…

ClinicalTrials.gov IDNCT07833085
PhaseNA
Enrollment100
SponsorZhongnan Hospital
Age18 Years and older
SexALL
I'm interested View official listing

Conditions studied

Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma, Lung Cancer (NSCLC), Breast Cancer

About this study

Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology; * Age of 18 years and above, both male and female are eligible; * The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points; * Research participants voluntarily sign informed consent forms or have their parents/children/legal guardians sign informed consent forms, and are able to complete the trial according to the requirements of the research protocol. Exclusion Criteria: * Participants with severe liver and kidney dysfunction and cardiac dysfunction; * Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans; * Pregnant or lactating women; * Other situations that researchers believe should be excluded and documented.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-20.